Catalyzing medical innovation in one of the world's best R&D environments
What Australia offers:
​
​World class institutions, scientists, innovators and KOL's
Government funding and support for research and development
Favourable clinical trial and tax environment and a world-leading R&D tax rebate
Strong healthcare infrastructure
Stable regulatory environment and harmonisation with other major jurisdictions
The ASX as a well-established vehicle for capital raising and liquidity for early-stage medical, biotech and pharmaceutical companies
​
​
Australia has one of the world’s most favourable ecosystems for medtech companies to thrive, with one key deficiency… access to knowledgeable and patient risk capital.
Bioshore’s mission is to fill that gap by investing in world leading medical technologies.
Our objective is to commercialise the best of the best to vastly improve patient outcomes and ultimately lower the cost to deliver healthcare globally
The Bioshore Team
Our General Partners, Advisory Board and Investment Committee have lived and breathed the MedTech commercialisation journey, with each of us bringing a different background and skillset to the group. Collectively, we have managed some of the largest global companies in MedTech, have run some of Australia's largest hospitals, have founded venture funds investing in novel medical technologies and have built MedTech companies from the ground up that have been acquired by multinationals and listed on the ASX. Put simply, there is no other venture fund in Australia with breadth of experience and track record of driving successful clinical and commercial outcomes in the medical technology sector.
“Healthtech and pharma companies backed by firms with deep expertise were far more likely to record a successful IPO or acquisition than their generalist peers—with exit success rates of 75.5% in healthtech and 82.6% in pharma. Those exits imply better returns for LPs” 'Life sciences VCs beat generalists in backing IPO and M&A-bound companies' Pitchbook News, October 2024
Bioshore Ventures Pty Limited
ABN 27 630 053 084
CAR No. 001314515
​
​
​
​
Contact us to learn more
​
​
2/20 Bond St
Sydney NSW
Australia 2000
​
​
This website is issued by Bioshore Capital Pty Ltd (ACN 684 995 560) (Bioshore Capital), the investment manager of which is a stapled fund which comprises an Early Stage Venture Capital Limited Partnership (ESVCLP Fund) and Bioshore Ventures Fund 1 which is an Australian Unit Trust (Unit Trust). Bioshore Capital is a Corporate Authorised Representative (AR 001314515) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) (Polar Advisory). The ESVCLP Fund is conditionally registered as an early stage venture capital limited partnership and further conditions will need to be met before being able to apply to be registered as a complying and fully registered early stage venture capital fund in accordance with the Venture Capital Act 2002 (Cth). Polar 993 Limited (ACN 642 129 226) (AFSL 525458) (Polar 993) is the trustee of the Unit Trust. The ESVCLP Fund Unit Trust are a stapled product and collectively known as the Stapled Fund (Stapled Fund). Bioshore's authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the ESVCLP Fund and the Unit Trust (known as the Stapled Fund) and only to wholesale clients. Polar 993 has entered into an Intermediary Authorisation Arrangement with Bioshore Ventures General Partner I LP the general partner of the ESVCLP Fund (General Partner), for the making of offers for the issuing, variation or disposal of interests in the ESVCLP Fund.